WO2021248083A1 - Composés hétérocycliques et leurs procédés d'utilisation - Google Patents

Composés hétérocycliques et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2021248083A1
WO2021248083A1 PCT/US2021/036025 US2021036025W WO2021248083A1 WO 2021248083 A1 WO2021248083 A1 WO 2021248083A1 US 2021036025 W US2021036025 W US 2021036025W WO 2021248083 A1 WO2021248083 A1 WO 2021248083A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
pharmaceutically acceptable
stereoisomers
mixture
acceptable salt
Prior art date
Application number
PCT/US2021/036025
Other languages
English (en)
Inventor
Jayakanth Kankanala
Jeremy D. Pettigrew
Son Minh Pham
Sarvajit Chakravarty
Jiyun Chen
Original Assignee
Sparcbio Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sparcbio Llc filed Critical Sparcbio Llc
Publication of WO2021248083A1 publication Critical patent/WO2021248083A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present disclosure relates to inhibitors of one or more isoforms of RAS, such as inhibitors of one or more of KRAS, HRAS and NRAS, or mutants thereof, such as G12D, G12V, G13D or G12C mutants thereof. Therapeutic methods of treating conditions and diseases using these inhibitors are also provided.
  • KRAS, HRAS and NRAS are members of the family of RAS genes that were the first human oncogenes to be discovered, and are frequently mutated in cancer.
  • a critical node in growth factor signaling pathways, KRAS for example, regulates the proliferation, survival, migration and differentiation of cells.
  • the protein is a monomeric GTPase that cycles between an inactive GDP-bound form and an active GTP-bound form, the active form interacting with downstream effector proteins to promote proliferation and other cellular processes.
  • Activating mutations in KRAS drive many cancers, including pancreatic cancer, lung adenocarcinoma and colorectal cancer.
  • the present disclosure provides compounds that inhibit activity of one or more members of the RAS family of proteins, such as one or more of the KRAS, HRAS and NRAS proteins, or mutants thereof, such as a G12D, G12V, G13D or G12C mutant thereof.
  • These compounds can be useful in treating cancer, in particular those cancers that are driven by activating mutations in either KRAS, HRAS or NRAS such as the G12C mutation.
  • the method comprises treating the disease.
  • a method of treating a KRAS-, HRAS- or NRAS-mediated disease in an individual at risk of developing the disease comprising administering an effective amount of a compound as described herein, or pharmaceutically acceptable salt thereof, to the individual.
  • the disease expresses a mutant RAS, such as a disease that expresses a G12D, G12V, G13D or G12C mutant.
  • the disease expresses KRAS G12C. In some embodiments, the disease expresses HRAS G12C. In some embodiments, the disease expresses NRAS G12C. In some embodiments, the disease is a cancer. In some embodiments, the cancer is lung, colorectal, or pancreatic cancer. In some embodiments, the cancer is MYH-associated polyposis, biliary tract cancer or hematologic malignancies. In some embodiments, the method further comprises administering an additional anti-cancer therapeutic agent, such as a chemotherapeutic agent.
  • an additional anti-cancer therapeutic agent such as a chemotherapeutic agent.
  • compositions including pharmaceutical compositions, that comprise a compound as detailed herein or a pharmaceutically acceptable salt thereof.
  • kits that comprise a compound as detailed herein or a pharmaceutically acceptable salt thereof, and methods of using (or administering) and making such compounds and pharmaceutically acceptable salts thereof.
  • the disclosure further provides compounds or compositions thereof for use in a method of treating a RAS-mediated disease, including a KRAS-, HRAS- or NRAS-mediated disease.
  • the disclosure provides uses of the compounds or compositions thereof in the manufacture of a medicament for the treatment of a KRAS-, HRAS- or NRAS -mediated disease.
  • the term “about” refers to a variation of ⁇ 1%, ⁇ 3%, ⁇ 5%, or ⁇ 10% of the value specified.
  • “about 50” can in some embodiments include a range of from 45 to 55.
  • the term “about” can include one or two integers greater than and/or less than a recited integer at each end of the range.
  • the term “about” is intended to include values, e.g., weight percentages, proximate to the recited range that are equivalent in terms of the functionality of the individual ingredient, the composition, or the embodiment.
  • Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X”.
  • alkyl refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 10 carbon atoms (i.e., C 1-10 alkyl or C 1 -C 10 alkyl), 1 to 8 carbon atoms (i.e., C 1-8 alkyl or C 1 -C 8 alkyl), 1 to 6 carbon atoms (i.e., C 1- 6 alkyl or C 1 -C 6 alkyl), or 1 to 4 carbon atoms (i.e., C 1-4 alkyl or C 1 -C 4 alkyl).
  • alkyl groups include, without limitation, methyl, ethyl, propyl, isopropyl, n-butyl, sec -butyl, isobutyl, tert-butyl, pentyl, 2- pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl and 3-methylpentyl.
  • alkyl residue having a specific number of carbons is named by chemical name or identified by molecular formula, all positional isomers having that number of carbons may be encompassed; thus, for example, “butyl” includes n-butyl (i.e.
  • -(CH 2 ) 3 CH 3 sec-butyl (i.e., - CH(CH 3 )CH 2 CH 3 ), isobutyl (i.e., -CH 2 CH(CH 3 ) 2 ) and tert-butyl (i.e., -C(CH 3 ) 3 ); and “propyl” includes n-propyl (i.e., -(CH 2 ) 2 CH 3 ) and isopropyl (i.e., -CH(CH 3 ) 2 ).
  • Alkylene refers to a divalent alkyl group as defined herein.
  • Haloalkyl refers to an unbranched or branched alkyl group as defined above, wherein one or more hydrogen atoms are replaced by a halogen. For example, where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached. Dihaloalkyl and trihaloalkyl refer to alkyl substituted with two (“di”) or three (“tri”) halo groups, which may be, but are not necessarily, the same halogen. Examples of haloalkyl include difluoromethyl (-CHF 2 ) and trifluoromethyl (-CF 3 ).
  • “Fletero alkyl” refers to an alkyl group in which one or more of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatomic group.
  • the term “heteroalkyl” includes unbranched or branched saturated chain having carbon and heteroatoms. By way of example, 1, 2 or 3 carbon atoms may be independently replaced with the same or different heteroatomic group. Heteroatomic groups include, but are not limited to, -NH-, -O-, -S-, -S(O)-, -S(O) 2 - and the like.
  • heteroalkyl includes 1 to 8 carbon atoms, or 1 to 4 carbon atoms; and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom.
  • Alkoxy refers to the group “-O-alkyl”. Examples of alkoxy groups include, without limitation, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec- butoxy, n-pentoxy, n-hexoxy and 1,2-dimethylbutoxy.
  • Alkenyl refers to an alkyl group containing at least one carbon-carbon double bond and having from 2 to 20 carbon atoms (i.e., C 2-20 alkenyl or C 2 -C 20 alkenyl), 2 to 8 carbon atoms (i.e., C 2-8 alkenyl or C 2 -C 8 alkenyl), 2 to 6 carbon atoms (i.e., C2-6 alkenyl or C 2 -C 6 alkenyl) or 2 to 4 carbon atoms (i.e., C2-4 alkenyl or C2-C4 alkenyl).
  • alkenyl groups include, without limitation, ethenyl, propenyl, and butadienyl (e.g., 1,2-butadienyl and 1,3-butadienyl).
  • Alkynyl refers to an alkyl group containing at least one carbon-carbon triple bond and having from 2 to 20 carbon atoms (i.e., C 2-20 alkynyl or C 2 -C 20 alkynyl), 2 to 8 carbon atoms (i.e., C 2-8 alkynyl or C 2 -C 8 alkynyl), 2 to 6 carbon atoms (i.e., C 2-6 alkynyl or C 2 -C 6 alkynyl) or 2 to 4 carbon atoms (i.e., C 2-4 alkynyl or C 2 -C 4 alkynyl).
  • alkynyl also includes those groups having one triple bond and one double bond.
  • Aryl refers to an aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic) including fused systems.
  • aryl has 6 to 20 ring carbon atoms (i.e., C 6-20 aryl or C 6 -C 20 aryl), 6 to 12 carbon ring atoms (i.e., C 6-12 aryl or C 6 -C 12 aryl), or 6 to 10 carbon ring atoms (i.e., C 6-10 aryl or C 6 -C 10 aryl).
  • aryl groups include, without limitation, phenyl, naphthyl, fluorenyl and anthryl. Aryl, however, does not encompass or overlap in any way with heteroaryl defined below. If one or more aryl groups are fused with a heteroaryl, the resulting ring system is heteroaryl. If one or more aryl groups are fused with a heterocyclyl, the resulting ring system is heterocyclyl.
  • Cycloalkyl refers to a saturated or partially unsaturated cyclic alkyl group having a single ring or multiple rings including fused, bridged and spiro ring systems.
  • the term “cycloalkyl” includes cycloalkenyl groups (i.e., the cyclic group having at least one double bond) and carbocyclic fused ring systems having at least one sp 3 carbon atom (i.e., at least one non-aromatic ring).
  • cycloalkyl has from 3 to 20 ring carbon atoms (i.e., C 3-20 cycloalkyl or C 3 -C 20 cycloalkyl), 3 to 12 ring carbon atoms (i.e., C 3-12 cycloalkyl or C 3 -C 12 cycloalkyl), 3 to 10 ring carbon atoms (i.e., C 3-10 cycloalkyl or C 3 -C 10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C 3-8 cycloalkyl or C 3 -C 8 cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C 3-6 cycloalkyl or or C 3 -C 6 cycloalkyl).
  • Monocyclic groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • cycloalkyl is intended to encompass any non-aromatic ring which may be fused to an aryl ring, regardless of the attachment to the remainder of the molecule.
  • cycloalkyl also includes “spirocycloalkyl” when there are two positions for substitution on the same carbon atom.
  • Heteroaryl refers to an aromatic group having a single ring, multiple rings or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen and sulfur.
  • heteroaryl includes 1 to 20 ring carbon atoms (i.e., C 1-20 heteroaryl), 3 to 12 ring carbon atoms (i.e., C 3-12 heteroaryl), or 3 to 8 carbon ring atoms (i.e., C 3-8 heteroaryl) and 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen and sulfur.
  • heteroaryl includes 5-12 membered ring systems, 5-10 membered ring systems, 5-7 membered ring systems, or 5-6 membered ring systems, each independently having 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen and sulfur. Any aromatic ring, having a single or multiple fused rings, containing at least one heteroatom, is considered a heteroaryl regardless of the attachment to the remainder of the molecule (i.e., through any one of the fused rings). Heteroaryl does not encompass or overlap with aryl as defined above.
  • Heterocyclyl refers to a saturated or partially unsaturated cyclic alkyl group, with one or more ring heteroatoms independently selected from nitrogen, oxygen and sulfur.
  • heterocyclyl includes heterocycloalkenyl groups (i.e., the heterocyclyl group having at least one double bond), bridged-heterocyclyl groups, fused-heterocyclyl groups and spiro-heterocyclyl groups.
  • Any non-aromatic ring containing at least one heteroatom is considered a heterocyclyl, regardless of the attachment (i.e., can be bound through a carbon atom or a heteroatom).
  • the term heterocyclyl is intended to encompass any non- aromatic ring containing at least one heteroatom, which ring may be fused to an aryl or heteroaryl ring, regardless of the attachment to the remainder of the molecule.
  • heterocyclyl has 2 to 20 ring carbon atoms (i.e., C 2-20 or C 2 -C 20 heterocyclyl), 2 to 12 ring carbon atoms (i.e., C 2-12 or C 2 -C 12 heterocyclyl), 2 to 10 ring carbon atoms (i.e., C 2-10 or C 2 -C 10 heterocyclyl), 2 to 8 ring carbon atoms (i.e., C 2-8 or C 2 -C 8 heterocyclyl), 3 to 12 ring carbon atoms (i.e., C 3-12 or C 3 -C 12 heterocyclyl), 3 to 8 ring carbon atoms (i.e., C 3-8 or C 3 -C 8 heterocyclyl), or 3 to 6 ring carbon atoms (i.e., C 3-6 or C 3 -C 6 heterocyclyl); having 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heterocyclyl),
  • heterocyclyl includes 3-12 membered ring systems, 5-10 membered ring systems, 5-7 membered ring systems, or 5-6 membered ring systems, each independently having 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen and sulfur.
  • heterocyclyl also includes “spiroheterocyclyl” when there are two positions for substitution on the same carbon atom.
  • Halogen or “halo” includes fluoro, chloro, bromo and iodo.
  • the terms “optional” or “optionally” means that the subsequently described event or circumstance may or may not occur.
  • the term “optionally substituted” refers to any one or more hydrogen atoms on the designated atom or group may or may not be replaced by a moiety other than hydrogen.
  • “Substituted” as used herein means one or more (e.g., 1-5, 1-4, 1-3, 1-2, 2-5, 2-4, 2-3, 3-5, or 3-4) hydrogen atoms of the group is replaced with a substituent atom or group commonly used in pharmaceutical chemistry. Each substituent can be the same or different.
  • substituents include, but are not limited to, hydrazide, halo, -CN, -NO2, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 56 , -C(O)0R 56 , - C(O)R 56 , -O-alkyl-OR 56 , alkyl-OR 56 , haloalkyl, haloalkoxy, -SR 56 , -S(O)R 56 , -SO2R 56 , - NR 56 R 57 , -C(O)NR 56 R 57 , -NR 56 C(O)R 57 , including seleno- and thio- derivatives thereof, wherein each R 56 and R 57 are independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, cycloalkyl-alkyl-, wherein
  • stereoisomers also are stereoisomers, mixture of stereoisomers, tautomers, hydrates, solvates, isotopically enriched analogs and pharmaceutically acceptable salts of the compounds described herein.
  • the compounds disclosed herein, or their pharmaceutically acceptable salts may include an asymmetric center and may thus give rise to enantiomers, diastereomers and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as ( R )- or (S)- or, as (D)- or (L)- for amino acids.
  • the present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms.
  • Optically active (+) and (-), ( R )- and ( S )-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents or resolved using conventional techniques, for example, chromatography and fractional crystallization.
  • a “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable.
  • the present disclosure contemplates various stereoisomers and mixtures thereof and includes “enantiomers,” which refers to two stereoisomers whose molecules are nonsuperimposable mirror images of one another and “diastereomers,” which refers to stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.
  • stereoisomers for example, geometric isomers, optical isomers and the like
  • the present compounds including those of the salts, solvates and hydrates of the compounds, such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers and diastereomeric forms, are contemplated.
  • Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher’s acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers.
  • an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher’s acid chloride
  • converting e.g., hydrolyzing
  • some of the compounds disclosed herein, e.g., Formula I may be atropisomers and are considered as part of this disclosure.
  • Stereoisomers can also be separated by use
  • Tautomers are in equilibrium with one another.
  • amide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown and regardless of the nature of the equilibrium among tautomers, the compounds are understood by one of ordinary skill in the art to comprise both amide and imidic acid tautomers. Thus, the amide containing compounds are understood to include their imidic acid tautomers. Fikewise, the imidic acid containing compounds are understood to include their amide tautomers.
  • any compound or structure given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. These forms of compounds may also be referred to as an “isotopically enriched analog.” Isotopically labeled compounds have structures depicted herein, except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
  • isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine and iodine, such as 2 H, 3 H, U C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 36 C 1 , 123 I and 125 I, respectively.
  • isotopically labeled compounds of the present disclosure for example those into which radioactive isotopes such as 3 H and 14 C are incorporated.
  • Such isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays or in radioactive treatment of patients.
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • Such compounds may exhibit increased resistance to metabolism and are thus useful for increasing the half-life of any compound when administered to a mammal, particularly a human.
  • Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens have been replaced by deuterium.
  • Certain compounds disclosed herein contain one or more ionizable groups (groups from which a proton can be removed (e.g., -COOH) or added (e.g., amines) or which can be quatemized (e.g., amines)). All possible ionic forms of such molecules and salts thereof are intended to be included individually in the disclosure herein. With regard to salts of the compounds described herein, one of ordinary skill in the art can select from among a wide variety of available counterions those that are appropriate. In specific applications, the selection of a given anion or cation for preparation of a salt may result in increased or decreased solubility of that salt.
  • inhibitor refers to the slowing, halting, or reversing the growth or progression of a disease, infection, condition, or group of cells.
  • the inhibition can be greater than about 20%, 40%, 60%, 80%, 90%, 95%, or 99%, for example, compared to the growth or progression that occurs in the absence of the treatment or contacting.
  • “Individual” as used herein is a mammal, including humans.
  • individuals includes pig, bovine, feline, canine, primate, rodent, or human.
  • the individual is human.
  • treatment is an approach for obtaining beneficial or desired results including clinical results.
  • beneficial or desired results include, but are not limited to, one or more of the following: decreasing one or more symptoms resulting from the disease or disorder, diminishing the extent of the disease or disorder, stabilizing the disease or disorder (e.g., preventing or delaying the worsening of the disease or disorder), delaying the occurrence or recurrence of the disease or disorder, delaying or slowing the progression of the disease or disorder, ameliorating the disease or disorder state, providing a remission (whether partial or total) of the disease or disorder, decreasing the dose of one or more other medications required to treat the disease or disorder, enhancing the effect of another medication used to treat the disease or disorder, delaying the progression of the disease or disorder, increasing the quality of life, and/or prolonging survival of a patient.
  • treatment is a reduction of pathological consequence of the disease or disorder.
  • the methods of this disclosure contemplate any one or more of
  • a combination therapy is meant a therapy that includes two or more different compounds or therapeutic agents.
  • a combination therapy comprising a compound detailed herein and another compound or therapeutic agent is provided.
  • the combination therapy optionally includes one or more pharmaceutically acceptable carriers or excipients, non-pharmaceutically active compounds and/or inert substances.
  • treatment with a combination therapy may result in an additive or even synergistic (e.g., greater than additive) result compared to administration of a single compound of the disclosure alone.
  • a lower amount of each compound is used as part of a combination therapy compared to the amount generally used for individual therapy.
  • the same or greater therapeutic benefit is achieved using a combination therapy than by using any of the individual compounds alone.
  • the same or greater therapeutic benefit is achieved using a smaller amount (e.g., a lower dose or a less frequent dosing schedule) of a compound in a combination therapy than the amount generally used for individual compound or therapy.
  • the use of a small amount of compound results in a reduction in the number, severity, frequency and/or duration of one or more side-effects associated with the compound.
  • an effective amount refers to an amount of a compound or composition sufficient to treat a specified disorder, condition or disease such as ameliorate, palliate, lessen, and/or delay one or more of its symptoms.
  • an effective amount comprises an amount sufficient to cause a tumor to shrink and/or to decrease the growth rate of the tumor (such as to suppress tumor growth) or to prevent or delay other unwanted cell proliferation.
  • an effective amount is an amount sufficient to delay development.
  • an effective amount is an amount sufficient to prevent or delay occurrence and/or recurrence.
  • An effective amount can be administered in one or more administrations.
  • the effective amount of the drug or composition may: (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, retard, slow to some extent and preferably stop cancer cell infiltration into peripheral organs; (iv) inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay occurrence and/or recurrence of tumor; and/or (vii) relieve to some extent one or more of the symptoms associated with the cancer.
  • carrier refers to relatively nontoxic chemical compounds or agents that facilitate the incorporation of a compound into cells or tissues.
  • pharmaceutically acceptable or “pharmacologically acceptable” is meant a material that is not biologically or otherwise undesirable, e.g., the material may be incorporated into a pharmaceutical composition administered to a patient without causing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained.
  • Pharmaceutically acceptable carriers or excipients have preferably met the required standards of toxicological and manufacturing testing and/or are included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug administration.
  • “Pharmaceutically acceptable salts” are those salts which retain at least some of the biological activity of the free (non- salt) compound and which can be administered as drugs or pharmaceuticals to an individual.
  • Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; or formed with organic acids such as acetic acid, oxalic acid, propionic acid, succinic acid, maleic acid, tartaric acid and the like; (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base.
  • a metal ion e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion
  • coordinates with an organic base e.g.
  • Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine and the like.
  • Acceptable inorganic bases include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide and the like.
  • Further examples of pharmaceutically acceptable salts include those listed in Berge et ah, Pharmaceutical Salts, J. Pharm. Sci. 1977 Jan;66(l):l-19.
  • Pharmaceutically acceptable salts can be prepared in situ in the manufacturing process, or by separately reacting a purified compound of the disclosure in its free acid or base form with a suitable organic or inorganic base or acid, respectively and isolating the salt thus formed during subsequent purification.
  • a reference to a pharmaceutically acceptable salt includes the solvent addition forms or crystal forms thereof, particularly solvates or polymorphs.
  • Solvates contain either stoichiometric or non- stoichiometric amounts of a solvent and are often formed during the process of crystallization. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol.
  • Polymorphs include the different crystal packing arrangements of the same elemental composition of a compound. Polymorphs usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability and solubility. Various factors such as the recrystallization solvent, rate of crystallization and storage temperature may cause a single crystal form to dominate.
  • excipient means an inert or inactive substance that may be used in the production of a drug or pharmaceutical, such as a tablet containing a compound of the disclosure as an active ingredient.
  • a drug or pharmaceutical such as a tablet containing a compound of the disclosure as an active ingredient.
  • Various substances may be embraced by the term excipient, including without limitation any substance used as a binder, disintegrant, coating, compression/encapsulation aid, cream or lotion, lubricant, solutions for parenteral administration, materials for chewable tablets, sweetener or flavoring, suspending/gelling agent, or wet granulation agent.
  • A is a 4-12 membered saturated or partially saturated monocyclic, bridged or spiro ring
  • B is N or C-CN
  • X 1 is C, CH, or N
  • Q is -0-, -S-, -NR C -, -CR a R b , or a bond; m is 0, 1, 2, or 3; n is 0, 1, 2, or 3;
  • R 1 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, -(C 1 -C 6 alkylene)OR a , -(C 1 -C 6 alkylene)NR a R b , -NR a R b , 3-12 membered heterocyclyl, C 3 -C 12 cycloalkyl, -(C 1 -C 6 alkylene) 3-12 membered heterocyclyl, C 6 -C 12 aryl, 5-12 membered heteroaryl, or -(C 1 -C 6 alkylene) 5-12 membered heteroaryl, each of which is optionally substituted with one or more R 1a ;
  • R 2 is C 3 -C 12 cycloalkyl, 3-12 membered heterocyclyl, 5-12 membered heteroaryl, or C 6 -C 12 aryl, each of which is optionally substituted with one or more R 2a ;
  • L is a bond, -C(O)-, C 1 -C 3 alkylene, -S(O)-, or -S(O) 2 -;
  • L 1 is -C(O)- or -S(O) 2 -;
  • R 2a and R 3 are each independently oxo, C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, halogen, hydroxyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, C 1 -C 6 alkyl, C 2 -C 6 alkynyl, C 1 -C 6 heteroalkyl, -CN, -OR f , -C(O)OR f , -C(O)N(R f R g ), or -N(R f R g ), each of which is optionally substituted with one or more substituents selected from -CN, halogen, -OR h , - N(R h R i ), and 5-12 membered heteroaryl; R 1a and R 4 are each independently hydrogen, -C(O)R f , hydroxyl, -(C 1 -C 6
  • R a and R b are each independently hydrogen, C 1 -C 6 alkyl, C 6 -C 12 aryl, 3-12 membered heterocyclyl, 5-12 membered heteroaryl, C 1 -C 6 haloalkyl, or C 3 -C 8 cycloalkyl, each of which is optionally substituted with one or more R 3 , or R a and R b are taken together with the atom to which they attach to form a 3 - 12 membered heterocyclic or 5-12 membered heteroaryl;
  • R f , R g , R h , and R 1 arc each independently hydrogen, C 1 -C 6 alkyl, C 6 -C 12 aryl, 3-12 membered heterocyclyl, 5-12 membered heteroaryl, C 1 -C 6 haloalkyl, or C 3 -C 8 cycloalkyl, or
  • R f and R g or R h and R 1 are taken together with the atom to which they attach to form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl.
  • a spiro ring system has at least two rings with one common atom. It is also understood that a fused ring system has at least two rings with two adjacent common atoms.
  • B is N.
  • B is C-CN.
  • the compound is of formula (II), wherein A, m, n, Q, L, L 1 , X 1 , R 1 , R 2 , R 3 , R 4 , R d and R e are as detailed herein for formula (I).
  • the compound is of formula (III), wherein A, m, n, Q, L, L 1 , X 1 , R 1 , R 2 , R 3 , R 4 , R d and R e are as detailed herein for formula (I).
  • Q is -0-.
  • Q is -S-.
  • Q is -NR C -.
  • Q is -NR C -; and R c is hydrogen.
  • Q is -NR C -; and R c is C 1 -C 3 alkyl.
  • Q is -NR C -; and R c is C 3 -C 6 cycloalkyl.
  • Q is a bond.
  • Q is -CR a R b .
  • B is N; and Q is -0-.
  • B is N; and Q is -S-.
  • B is N; and Q is -NR C -.
  • B is N; Q is -NR C -; and R c is hydrogen.
  • B is N; Q is -NR C -; and R c is C 1 -C 3 alkyl.
  • B is N; Q is -NR C -; and R c is C 3 -C 6 cycloalkyl.
  • B is N; and Q is a bond.
  • B is N; and Q is -CR a R b . In some embodiments, B is C-CN; and Q is -0-. In some embodiments, B is C-CN; and Q is -S-. In some embodiments,
  • B is C-CN; and Q is -NR C -.
  • B is C-CN; Q is -NR C -; and R c is hydrogen.
  • B is C-CN; Q is -NR C -; and R c is C 1 -C 3 alkyl.
  • B is C-CN; Q is -NR C -; and R c is C 3 -C 6 cycloalkyl.
  • B is C-CN; and Q is a bond.
  • B is C-CN; and Q is -CR a R b .
  • X 1 is C. In some embodiments, X 1 is N. In some embodiments, X 1 is CH.
  • A is a 4-12 membered saturated or partially saturated monocyclic ring.
  • A is 6-membered saturated or partially saturated monocyclic ring.
  • A is a 5-12 membered saturated or partially saturated bridged ring.
  • A is a 4-12 membered saturated or partially saturated fused ring.
  • A is a 4-12 membered saturated monocyclic ring.
  • A is 6-membered saturated monocyclic ring.
  • A is a 5-12 membered saturated bridged ring.
  • A is a 4-12 membered saturated fused ring.
  • a and R 3 together are , wherein * denotes point of attachment to L 1 . It is understood that when A is a spiro or fused ring, any part of the ring can be substituted by R 3 . In some embodiments, A , In some embodiments, A and R 3 together are In some embodiments, A and R 3 together are . In some embodiments, A and R 3
  • each R 3 substituent on A is independently C 1 -C 6 alkyl optionally substituted with one or more substituents selected from -CN, halogen, -OR h , -N(R h R') and 5-12 membered heteroaryl.
  • each R 3 substituent on A is independently methyl or -CH 2 CN.
  • a and R 3 together are
  • L 1 is -C(O)-. In some embodiments, L 1 is -S(O) 2 -.
  • a compound of formula (I) or any related formula where applicable, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, solvate, or tautomer thereof is a double bond.
  • L 1 is -C(O)-; and is a double bond.
  • L 1 is -C(O)-; and is a triple bond and R d is absent.
  • L 1 is -S(O) 2 -; and is a double bond.
  • L 1 is -S(O) 2 -; and is a triple bond and R d is absent.
  • the compound is of any one of formulae (I-a)-(I-l), wherein B, m, n, Q, L, L 1 , X 1 , R 1 , R 2 , R 3 , R 4 , R d and R e are as detailed herein for formula (I).
  • the compound is of any one of formulae (Il-a)-(II-l), wherein B, m, n, Q, L, L 1 , X 1 , R 1 , R 2 , R 3 , R 4 , R d and R e are as detailed herein for formula (I).
  • the compound is of any one of formulae (Ill-a)-(III-l), wherein B, m, n, Q, L, L 1 , X 1 , R 1 , R 2 , R 3 , R d and R e are as detailed herein for formula (I).
  • L is a bond.
  • L is -C(O)-.
  • L is C 1 -C 3 alkylene.
  • L is -S(O)-.
  • L is -S(O) 2 -.
  • R 1 is hydrogen.
  • R 1 is C 1 -C 6 alkyl, which is optionally substituted with one or more R 1a .
  • R 1 is C 1 -C 6 haloalkyl, which is optionally substituted with one or more R 1a .
  • R 1 is -(C 1 -C 6 alkylene)OR a , which is optionally substituted with one or more R 1a .
  • R 1 is -(C 1 -C 6 alkylene)NR a R b , which is optionally substituted with one or more R 1a .
  • R 1 is -NR a R b , which is optionally substituted with one or more R 1a .
  • R 1 is 3-12 membered heterocyclyl, which is optionally substituted with one or more R 1a .
  • R 1 is C 3 -C 12 cycloalkyl, which is optionally substituted, with one or more R 1a .
  • R 1 is -(C 1 -C 6 alkylene) 3-12 membered heterocyclyl, which is optionally substituted with one or more R 1a .
  • R 1 is C 6 -C 12 aryl, which is optionally substituted with one or more R 1a .
  • R 1 is C 6 -C 12 aryl, which is optionally substituted with one or more R 1a .
  • R 1 is 5-12 membered heteroaryl, which is optionally substituted with one or more R 1a .
  • R 1 is -(C 1 -C 6 alkylene) 5-12 membered heteroaryl, which is optionally substituted with one or more R 1a .
  • R 1 is C 1 -C 6 alkyl, -(C 1 -C 6 alkylene)NR a R b , 3-12 membered heterocyclyl, or -(C 1 -C 6 alkylene) 3-12 membered heterocyclyl, each of which is optionally substituted with one or more R 1a .
  • R 1 is ethyl, propyl,
  • each R 1a is independently -N(R f R g ) , C 1 -C 6 alkyl, or -C(O)N(R f R g ). In some embodiments, , each of which is optionally substituted with one or more R 1a . In some embodiments, each R 1a is independently -N(R f R g ) , C 1 -C 6 alkyl, or -C(O)N(R f R g ). In some
  • R d is H.
  • R d is halogen.
  • R d is -CN.
  • R d is -C(O)OR f .
  • R d is C 1 -C 6 haloalkyl.
  • R d is C 1 -C 6 alkyl.
  • R d is C 1 - C 6 heteroalkyl.
  • R d is -C(O)N(R f R g ). In some embodiments, R d is C 6 - C 12 aryl. In some embodiments, R d is 5-12 membered heteroaryl. In some embodiments, R d is 3-12 membered heterocyclyl. In some embodiments, R d is -(C 1 -C 6 alkylene)OR f . In some embodiments, R d is -(C 1 -C 6 alkylene)N(R f R g ). In some embodiments, R d is H, halogen, -CN, or C 1 -C 6 alkyl.
  • R e is H. In some embodiments, R e is halogen. In some embodiments, R e is -CN. In some embodiments, R e is -C(O)OR f . In some embodiments, R e is C 1 -C 6 haloalkyl. In some embodiments, R e is C 1 -C 6 alkyl. In some embodiments, R e is C 1 -C 6 heteroalkyl.
  • R e is -C(O)N(R f R g ). In some embodiments, R e is C 6 -C 12 aryl. In some embodiments, R e is 5-12 membered heteroaryl. In some embodiments, R e is 3- 12 membered heterocyclyl. In some embodiments, R e is -(C 1 -C 6 alkylene)OR f . In some embodiments, R e is -(C 1 -C 6 alkylene)N(R f R g ). In some embodiments, R e is H, C 1 -C 6 alkyl, or -(C 1 -C 6 alkylene)N(R f R g ) .
  • R d and R e are each independently H, halogen, -CN, C 1 -C 6 alkyl, or -(C 1 -C 6 alkylene)N(R f R g ). In some embodiments,
  • R e and R f are each independently H, halogen, -CN, C 1 -C 6 alkyl, or -(C 1 -C 6 alkylene)N(R g R h ). In some embodiments, some embodiments, some embodiments, R e and R f are each independently H, halogen, -CN, C 1 -C 6 alkyl, or -(C 1 -
  • R 2 is C 3 -C 12 cycloalkyl optionally substituted with one or more R 2a .
  • R 2 is 3-12 membered heterocyclyl optionally substituted with one or more R 2a .
  • R 2 is 5-6 membered heterocyclyl optionally substituted with R 2a .
  • R 2 is C 6 -C 12 aryl optionally substituted with one or more R 2a .
  • R 2 is phenyl optionally substituted with one or more R 2a . In some embodiments, R 2 is 5-12 membered heteroaryl optionally substituted with one or more R 2a . In some embodiments, R 2 is 5-6 membered heteroaryl optionally substituted with one or more R 2a .
  • each R 2a is independently hydroxyl, C 1 -C 6 alkyl, halogen, or -N(R f R g ). In some embodiments,
  • R 2 is which is optionally substituted with one or more R 2a In some embodiments, which is optionally substituted with one or more R 2a . In some embodiments, which is optionally substituted with one or more R 2a . In some embodiments, which is optionally substituted with one or more R 2a . In some embodiments, which is optionally substituted with one or more R 2a . In some embodiments, which is optionally substituted with one or more R 2a .
  • R 2 which is optionally substituted with one or more R 2a . In some embodiments, which is optionally substituted with one or more R 2a . In some embodiments, R 2 is which is optionally substituted with one or more R 2a . In some embodiments, which is optionally substituted with one or more R 2a . In some embodiments, each R 2a is independently hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, halogen, or -N(R g R h ). In some embodiments,
  • n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 0, 1, or 2. In some embodiments, n is 0 or 1. In some embodiments, n is 1 or 2.
  • each R 4 is independently -C(0)R f , which is optionally substituted with one or more substituents selected from -OR h , C 3 -C 12 cycloalkyl, and -CN. In some embodiments, when R 4 is present, each R 4 is independently hydroxyl.
  • each R 4 when R 4 is present, each R 4 is independently -(C 1 -C 6 alkylene)OR f , which is optionally substituted with one or more substituents selected from -OR h , C 3 -C 12 cycloalkyl, and -CN. In some embodiments, when R 4 is present, each R 4 is independently - CN. In some embodiments, when R 4 is present, each R 4 is independently halogen. In some embodiments, when R 4 is present, each R 4 is independently C 1 -C 6 alkyl, which is optionally substituted with one or more substituents selected from -OR h , C 3 -C 12 cycloalkyl, and -CN.
  • each R 4 when R 4 is present, each R 4 is independently -(C 1 -C 6 alkylene) C 6 -C 12 aryl, which is optionally substituted with one or more substituents selected from -OR h , C 3 -C 12 cycloalkyl, and -CN. In some embodiments, when R 4 is present, each R 4 is independently C 1 - C 6 haloalkyl, which is optionally substituted with one or more substituents selected from - OR h , C 3 -C 12 cycloalkyl, and -CN.
  • each R 4 when R 4 is present, each R 4 is independently C 3 -C 8 cycloalkyl, which is optionally substituted with one or more substituents selected from -OR h , C 3 -C 12 cycloalkyl, and -CN. In some embodiments, when R 4 is present, each R 4 is independently 3-12 membered heterocyclyl, which is optionally substituted with one or more substituents selected from -OR h , C 3 -C 12 cycloalkyl, and -CN.
  • R 4 when R 4 is present, C -(C 1 -C 6 alkylene) 3-12 membered heterocyclyl, which is optionally substituted with one or more substituents selected from -OR h , C 3 -C 12 cycloalkyl, and -CN.
  • each R 4 when R 4 is present, is independently C 1 -C 6 alkoxy, which is optionally substituted with one or more substituents selected from -OR h , C 3 -C 12 cycloalkyl, and -CN.
  • each R 4 when R 4 is present, each R 4 is independently - (C 1 -C 6 alkylene)C(O)N(R f R g ), which is optionally substituted with one or more substituents selected from -OR h , C 3 -C 12 cycloalkyl, and -CN. In some embodiments, when R 4 is present, each R 4 is independently -(C 1 -C 6 alkylene)N(R f R g ), which is optionally substituted with one or more substituents selected from -OR h , C 3 -C 12 cycloalkyl, and -CN.
  • each R 4 when R 4 is present, each R 4 is independently -S(O) 2 R f , which is optionally substituted with one or more substituents selected from -OR h , C 3 -C 12 cycloalkyl, and -CN. In some embodiments, when R 4 is present, each R 4 is independently -C(O)OR f , which is optionally substituted with one or more substituents selected from -OR h , C 3 -C 12 cycloalkyl, and -CN.
  • each R 4 when R 4 is present, each R 4 is independently -C(O)N(R f R g ), which is optionally substituted with one or more substituents selected from -OR h , C 3 -C 12 cycloalkyl, and -CN. In some embodiments, when R 4 is present, each R 4 is independently -N(R f R g ) , which is optionally substituted with one or more substituents selected from -OR h , C 3 -C 12 cycloalkyl, and -CN.
  • the compounds of Formula I or any related formula where applicable selectively react with the G12C mutant KRAS, HRAS or NRAS proteins to form a covalent bond.
  • the compounds react with the cysteine at position 12 of a G12C mutant KRAS, HRAS or NRAS protein to form a covalent bond.
  • Exemplary compounds provided by the present disclosure include, but are not limited to, a compound, shown in Table 1, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotope or pharmaceutically acceptable salt thereof.
  • the compound is selected from the group consisting of Compound Nos. 1-77.
  • the compound is selected from the group consisting of Compound Nos. 1-88. Table 1
  • the compounds described herein antagonize activity of one or more RAS isoforms, such as KRAS, HRAS, NRAS, or a mutant thereof.
  • a method of treating diseases or conditions that are mediated by KRAS, HRAS, NRAS, or a mutant thereof comprises treating the diseases or conditions.
  • the disease is cancer and the treatment comprises administering an effective amount of a compound, pharmaceutically acceptable salt thereof, or composition as described herein to an individual in need thereof.
  • the compounds provided herein reduce tumor volume.
  • the compounds provided herein reduce cell proliferation.
  • the compounds provided herein prevent tumor metastasis.
  • beneficial or desired clinical results include, but are not limited to, alleviation of a symptom and/or diminishment of the extent of a symptom and/or preventing a worsening of a symptom associated with a disease or condition.
  • beneficial or desired clinical results include, but are not limited to, alleviation of a symptom and/or diminishment of the extent of a symptom and/or preventing a worsening of a symptom associated with a cancer.
  • treatment of a disease or condition with a compound of the disclosure or a pharmaceutically acceptable salt thereof is accompanied by no or fewer side effects than are associated with currently available therapies for the disease or condition and/or improves the quality of life of the individual.
  • the present disclosure provides a method of treating a disease or condition mediated by KRAS, HRAS, NRAS, or a mutant thereof, comprising administering to an individual in need thereof a compound provided herein or a pharmaceutically acceptable salt thereof.
  • the disease or condition is a cancer.
  • the disease or condition is pancreatic cancer, lung adenocarcinoma or colorectal cancer.
  • the disease or condition is MYH-associated polyposis, biliary tract cancer or a hematologic malignancy.
  • the methods of treatment in some embodiments comprise administering a compound provided herein or a pharmaceutically acceptable salt thereof as part of a combination therapy to treat the disease or condition.
  • the method of treatment comprises inhibiting or antagonizing a mutant KRAS, such as KRAS G12D, KRAS G12V, KRAS G13D or KRAS G12C.
  • the method comprises inhibiting an oncogenic form or oncogenic mutant of KRAS.
  • the method comprises inhibiting KRAS G12C.
  • the method of treatment comprises inhibiting or antagonizing a mutant HRAS, such as HRAS G12D, HRAS G12V, HRAS G13D or HRAS G12C.
  • the method comprises inhibiting an oncogenic form or oncogenic mutant of HRAS.
  • the method comprises inhibiting HRAS G12C.
  • the method of treatment comprises inhibiting or antagonizing a mutant NRAS, such as NRAS G12D, NRAS G12V, NRAS G13D or NRAS G12C.
  • a mutant NRAS such as NRAS G12D, NRAS G12V, NRAS G13D or NRAS G12C.
  • the method comprises inhibiting an oncogenic form or oncogenic mutant of NRAS.
  • the method comprises inhibiting NRAS G12C.
  • the method of treatment comprises inhibiting or antagonizing a mutant RAS, such as a RAS G12D, RAS G12V, RAS G13D or RAS G12C.
  • a mutant RAS such as a RAS G12D, RAS G12V, RAS G13D or RAS G12C.
  • the method comprises inhibiting an oncogenic form or oncogenic mutant of RAS. In some embodiments, the method comprises inhibiting RAS G12C, RAS G12D or RAS G12V.
  • the compounds provided herein reduce cell proliferation.
  • cell proliferation is reduced by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%.
  • cancer refers to a class of diseases of mammals characterized by uncontrolled cellular growth.
  • cancer is used interchangeably with the terms “tumor,” “solid tumor,” “malignancy,” “hyperproliferation” and “neoplasm.”
  • Cancer includes all types of hyperproliferative growth, hyperplasic growth, neoplastic growth, cancerous growth or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness.
  • Illustrative examples include, lung, prostate, head and neck, pancreatic, breast and colorectal cancer, melanomas and gliomas (such as a high grade glioma, including glioblastoma multiforme (GBM), the most common and deadliest of malignant primary brain tumors in adult humans).
  • melanomas and gliomas such as a high grade glioma, including glioblastoma multiforme (GBM), the most common and deadliest of malignant primary brain tumors in adult humans.
  • GBM glioblastoma multiforme
  • solid tumor includes, for example, lung cancer, head and neck cancer, brain cancer, oral cancer, colorectal cancer, breast cancer, prostate cancer, pancreatic cancer and liver cancer.
  • Other types of solid tumors are named for the particular cells that form them, for example, sarcomas formed from connective tissue cells (for example, bone cartilage, fat), carcinomas formed from epithelial tissue cells (for example, breast, colon, pancreas) and lymphomas formed from lymphatic tissue cells (for example, lymph nodes, spleen, thymus). Treatment of all types of solid tumors regardless of naming convention is within the scope of this disclosure.
  • the cancer can be a blood cancer, lung cancer, breast cancer, colorectal cancer, fallopian tube cancer, brain cancer, head and neck cancer, esophageal cancer, ovarian cancer, pancreatic cancer, peritoneal cancer, prostate cancer or skin cancer, such as, but not limited to, liver cancer, melanoma, Hodgkin’s disease, non-Hodgkin’s lymphomas, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, neuroblastoma, breast carcinoma, ovarian carcinoma, lung carcinoma, Wilms’ tumor, cervical carcinoma, testicular carcinoma, soft-tissue sarcoma, chronic lymphocytic leukemia, primary macroglobulinemia, bladder carcinoma, chronic granulocytic leukemia, primary brain carcinoma, malignant melanoma, small-cell lung carcinoma, stomach carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, malignant melanoma
  • Also provided is a method of treating bladder cancer, breast cancer, colorectal cancer, fallopian tube cancer, ovarian cancer, prostate cancer, non-small cell lung cancer, pancreatic cancer, peritoneal cancer, testicular cancer, endometrial cancer, or uterine cancer comprising administering an effective amount of a compound or composition as described herein, or a pharmaceutically acceptable salt or solvate thereof, to an individual in need thereof.
  • the method comprises treating bladder cancer, breast cancer, colorectal cancer, fallopian tube cancer, ovarian cancer, prostate cancer, non-small cell lung cancer, pancreatic cancer, peritoneal cancer, testicular cancer, endometrial cancer, or uterine cancer.
  • the method comprises treating cancer.
  • the compounds provided herein also modulate the function of KRAS, HRAS or NRAS and include compounds that are, for example, selective antagonists of KRAS, HRAS or NRAS.
  • the present compounds are useful in the treatment of RAS-associated conditions.
  • a “RAS-associated condition,” as used herein, denotes a condition or disorder which can be treated by modulating the function or activity of KRAS, HRAS or NRAS in a subject, wherein treatment comprises partial alleviation or cure of the condition or disorder. Modulation can occur locally, for example, within certain tissues of the subject, or more extensively throughout a subject being treated for such a condition or disorder.
  • the compounds provided herein reduce tumor volume. In some embodiments, the compounds reduce tumor volume by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%. [0089] In some embodiments, the compounds provided herein reduce KRAS signaling. In some embodiments, the compounds provided herein reduce the level of phosphorylated extracellular signal-regulated kinase (ERK). In some embodiments, the level of phosphorylated ERK is reduced at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%.
  • ERK extracellular signal-regulated kinase
  • the compounds provided herein reduce the level of activated KRAS. In some embodiments, the compounds provided herein reduce the level of KRAS-bound to GTP. In some embodiments, the level of KRAS-GTP is reduced by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%.
  • the compounds with potent antagonistic activity are used for the treatment of KRAS related lung cancer, colorectal cancer, or pancreatic cancer.
  • compositions including pharmaceutical compositions, of any of the compounds detailed herein are embraced by this disclosure.
  • pharmaceutical compositions comprising a compound of the disclosure, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
  • the pharmaceutical compositions provided herein may take a form suitable for oral, buccal, parenteral (e.g., intravenous, intramuscular, infusion or subcutaneous injection), nasal, topical or rectal administration, or a form suitable for administration by inhalation.
  • a compound as described herein may, in one aspect, be in a purified form.
  • Compositions comprising a compound as described herein, or a salt thereof, are provided, such as compositions of substantially pure compounds.
  • a composition comprising a compound as described herein, or a salt thereof is in substantially pure form.
  • substantially pure refers to a composition which contains no more than 35% impurity, wherein the impurity denotes a compound other than the desired compound, or a salt thereof, which comprises the majority of the composition.
  • a composition of substantially pure compound, or a salt thereof is provided wherein the composition contains no more than 25% impurity.
  • a composition of substantially pure compound, or a salt thereof wherein the composition contains or no more than 20% impurity. In still another variation, a composition of substantially pure compound, or a salt thereof, is provided wherein the composition contains or no more than 10% impurity. In a further variation, a composition of substantially pure compound, or a salt thereof, is provided wherein the composition contains or no more than 5% impurity. In another variation, a composition of substantially pure compound, or a salt thereof, is provided wherein the composition contains or no more than 3% impurity. In still another variation, a composition of substantially pure compound, or a salt thereof, is provided wherein the composition contains or no more than 1% impurity. In a further variation, a composition of substantially pure compound, or a salt thereof, is provided wherein the composition contains or no more than 0.5% impurity.
  • compositions are formulated in any manner, including using one or more physiologically acceptable carriers comprising excipients and/or auxiliaries which facilitate processing of the active compounds into pharmaceutical compositions.
  • physiologically acceptable carriers comprising excipients and/or auxiliaries which facilitate processing of the active compounds into pharmaceutical compositions.
  • proper formulation is dependent upon the route of administration chosen.
  • any techniques, carriers and excipients are used as suitable.
  • compositions that include a compound described herein and a pharmaceutically acceptable diluent(s), excipient(s) and/or carrier(s).
  • the compounds described herein are administered as pharmaceutical compositions in which compounds described herein are mixed with other active ingredients, as in combination therapy.
  • a pharmaceutical composition refers to a mixture of a compound described herein with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents and/or excipients.
  • a pharmaceutical composition facilitates administration of the compound to an organism.
  • practicing the methods of treatment or use provided herein includes administering or using a pharmaceutical composition comprising a therapeutically effective amount of a compound provided herein.
  • the methods of treatment provided for herein include administering such a pharmaceutical composition to a mammal having a disease or condition to be treated. In one embodiment, the mammal is a human.
  • the therapeutically effective amount varies widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors.
  • the compounds described herein are used singly or in combination with one or more therapeutic agents as components of mixtures.
  • the pharmaceutical compositions provided herein are formulated for intravenous injections.
  • the intravenous injection formulations provided herein are formulated as aqueous solutions and, in some embodiments, in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer.
  • the pharmaceutical compositions provided herein are formulated for transmucosal administration.
  • transmucosal formulations include penetrants appropriate to the barrier to be permeated.
  • the pharmaceutical compositions provided herein are formulated for other parenteral injections, appropriate formulations include aqueous or nonaqueous solutions and in one embodiment, with physiologically compatible buffers or excipients.
  • the pharmaceutical compositions provided herein are formulated for oral administration.
  • the oral formulations provided herein comprise compounds described herein that are formulated with pharmaceutically acceptable carriers or excipients.
  • Such carriers enable the compounds described herein to be formulated as tablets, powders, pills, dragees, capsules, liquids, gels, syrups, elixirs, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
  • compositions for oral use are obtained by mixing one or more solid excipient with one or more of the compounds described herein, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
  • Suitable excipients include, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as: for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others such as: polyvinylpyrrolidone (PVP or povidone) or calcium phosphate.
  • disintegrating agents are optionally added, such as the cross-linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • a pharmaceutical composition formulated as dragee cores with suitable coatings is provided herein.
  • concentrated sugar solutions are used in forming the suitable coating and optionally contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
  • dyestuffs and/or pigments are added to tablets, dragees and/or the coatings thereof for, e.g., identification or to characterize different combinations of active compound doses.
  • compositions which are used include orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push-fit capsules contain the active ingredients in admixture with filler such as lactose, binders such as starches and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds are dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • suitable liquids such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers are optionally added.
  • the formulations for oral administration are in dosages suitable for such administration.
  • the pharmaceutical compositions provided herein are formulated for buccal or sublingual administration.
  • buccal or sublingual compositions take the form of tablets, lozenges, or gels formulated in a conventional manner.
  • parenteral injections involve bolus injection or continuous infusion.
  • formulations for injection are presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
  • the pharmaceutical composition described herein is in a form suitable for parenteral injection as a sterile suspensions, solutions or emulsions in oily or aqueous vehicles and optionally contains formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form.
  • suspensions of the active compounds are prepared as appropriate oily injection suspensions.
  • Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
  • aqueous injection suspensions contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • the suspensions also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • the active ingredient is in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • the compounds described herein are administered topically.
  • the compounds described herein are formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams or ointments.
  • Such pharmaceutical compounds optionally contain solubilizers, stabilizers, tonicity enhancing agents, buffers and/or preservatives.
  • the pharmaceutical compositions provided herein are formulated for transdermal administration of compounds described herein.
  • administration of such compositions employs transdermal delivery devices and transdermal delivery patches.
  • the compositions are lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive.
  • patches include those constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
  • transdermal delivery of the compounds described herein is accomplished by use of iontophoretic patches and the like.
  • the rate of absorption is slowed by using rate-controlling membranes or by trapping the compound within a polymer matrix or gel.
  • absorption enhancers are optionally used to increase absorption.
  • Absorption enhancer and carrier include absorbable pharmaceutically acceptable solvents that assist in passage of the compound through the skin.
  • transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound to the skin of the host at a controlled and predetermined rate over a prolonged period of time and means to secure the device to the skin.
  • the pharmaceutical compositions provided herein are formulated for administration by inhalation.
  • the compounds described herein are in a form as an aerosol, a mist or a powder.
  • pharmaceutical compositions described herein are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit is determined by providing a valve to deliver a metered amount.
  • capsules and cartridges of, such as, by way of example only, gelatin for use in an inhaler or insufflator is formulated containing a powder mix of the compound described herein and a suitable powder base such as lactose or starch.
  • the compounds described herein are formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas.
  • rectal compositions optionally contain conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG and the like.
  • a low-melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter is first melted.
  • the pharmaceutical compositions are formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into pharmaceutically acceptable preparations.
  • proper formulation is dependent upon the route of administration chosen.
  • any of the techniques, carriers and excipients is used as suitable.
  • pharmaceutical compositions comprising a compound described herein are manufactured in a conventional manner, such as, by way of example only, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
  • the pharmaceutical compositions include at least one pharmaceutically acceptable carrier, diluent or excipient and a compound described herein described herein as an active ingredient in free-acid or free-base form, or in a pharmaceutically acceptable salt form.
  • the methods and pharmaceutical compositions described herein include the use of N-oxides, crystalline forms (also known as polymorphs), as well as active metabolites of these compounds having the same type of activity.
  • compounds described herein exist as tautomers. All tautomers are included within the scope of the compounds presented herein. Additionally, included herein are the solvated and unsolvated forms of the compounds described herein.
  • Solvated compounds include those that are solvated with pharmaceutically acceptable solvents such as water, ethanol and the like.
  • the solvated forms of the compounds presented herein are also considered to be disclosed herein.
  • the pharmaceutical compositions described herein include other medicinal or pharmaceutical agents, carriers, adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers.
  • the pharmaceutical compositions described herein also contain other therapeutically valuable substances.
  • compositions containing the compounds described herein include formulating the compounds with one or more inert, pharmaceutically acceptable excipients or carriers to form a solid, semi-solid or liquid.
  • Solid compositions include, but are not limited to, powders, tablets, dispersible granules, capsules, cachets and suppositories.
  • Liquid compositions include solutions in which a compound is dissolved, emulsions comprising a compound, or a solution containing liposomes, micelles, or nanoparticles comprising a compound as disclosed herein.
  • Semi-solid compositions include, but are not limited to, gels, suspensions and creams.
  • compositions are in liquid solutions or suspensions, solid forms suitable for solution or suspension in a liquid prior to use, or as emulsions.
  • These compositions optionally contain minor amounts of nontoxic, auxiliary substances, such as wetting or emulsifying agents, pH buffering agents and so forth.
  • a composition comprising a compound described herein takes the form of a liquid where the agents are present in solution, in suspension or both.
  • a first portion of the agent is present in solution and a second portion of the agent is present in particulate form, in suspension in a liquid matrix.
  • a liquid composition includes a gel formulation. In other embodiments, the liquid composition is aqueous.
  • Useful aqueous suspensions optionally contain one or more polymers as suspending agents.
  • Useful polymers include water-soluble polymers such as cellulosic polymers, e.g., hydroxypropyl methylcellulose and water- insoluble polymers such as cross- linked carboxyl-containing polymers.
  • Useful compositions optionally comprise an mucoadhesive polymer, selected for example from carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methylmethacrylate), polyacrylamide, polycarbophil, acrylic acid/butyl acrylate copolymer, sodium alginate and dextran.
  • compositions optionally include solubilizing agents to aid in the solubility of a compound described herein.
  • solubilizing agent generally includes agents that result in formation of a micellar solution or a true solution of the agent.
  • Solubilizing agents include certain acceptable nonionic surfactants, for example polysorbate 80 and ophthalmologically acceptable glycols, polyglycols, e.g., polyethylene glycol 400 and glycol ethers.
  • Useful compositions optionally include one or more pH adjusting agents or buffering agents, including acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane; and buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride.
  • acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids
  • bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane
  • buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride.
  • Such acids, bases and buffers are included in an amount required to maintain pH of the composition in an acceptable range.
  • Useful compositions optionally include one or more salts in an amount required to bring osmolality of the composition into an acceptable range.
  • Such salts include those having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions; suitable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate.
  • compositions optionally include one or more preservatives to inhibit microbial activity.
  • Suitable preservatives include mercury-containing substances such as merfen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride.
  • compositions optionally include one or more surfactants to enhance physical stability or for other purposes.
  • Suitable nonionic surfactants include polyoxyethylene fatty acid glycerides and vegetable oils, e.g., polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylene alkylethers and alkylphenyl ethers, e.g., octoxynol 10, octoxynol 40.
  • compositions optionally one or more antioxidants to enhance chemical stability where required.
  • Suitable antioxidants include, by way of example only, ascorbic acid and sodium metabisulfite.
  • aqueous suspension compositions are packaged in singledose non-reclo sable containers.
  • multiple-dose reclosable containers are used, in which case it is typical to include a preservative in the composition.
  • any delivery system for hydrophobic pharmaceutical compounds is employed.
  • Liposomes and emulsions are examples of delivery vehicles or carriers for hydrophobic drugs.
  • certain organic solvents such as N- methylpyrrolidone are employed.
  • the compounds are delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent.
  • sustained-release materials are utilized in the embodiments herein.
  • sustained-release capsules release the compounds for a few weeks up to over 100 days.
  • additional strategies for protein stabilization are employed.
  • the formulations or compositions described herein benefit from and/or optionally comprise antioxidants, metal chelating agents, thiol containing compounds and other general stabilizing agents.
  • stabilizing agents include, but are not limited to: (a) about 0.5% to about 2% w/v glycerol, (b) about 0.1% to about 1% w/v methionine, (c) about 0.1% to about 2% w/v monothioglycerol, (d) about 1 mM to about 10 mM EDTA, (e) about 0.01% to about 2% w/v ascorbic acid, (f) 0.003% to about 0.02% w/v polysorbate 80, (g) 0.001% to about 0.05% w/v.
  • polysorbate 20 (h) arginine, (i) heparin, (j) dextran sulfate, (k) cyclodextrins, (1) pentosan polysulfate and other heparinoids, (m) divalent cations such as magnesium and zinc; or (n) combinations thereof.
  • the compounds described herein are used in the preparation or manufacture of medicaments for the treatment of diseases or conditions that are mediated through RAS mutations, such as G12D, G12V, G13D and G12C KRAS, HRAS or NRAS.
  • a method for treating any of the diseases or conditions described herein in a subject in need of such treatment involves administration of pharmaceutical compositions containing at least one compound described herein, or a pharmaceutically acceptable salt, pharmaceutically acceptable N-oxide, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof, in therapeutically effective amounts to said subject.
  • compositions containing the compound(s) described herein are administered for therapeutic treatments.
  • the compositions are administered to a patient already suffering from a disease or condition, in an amount sufficient to cure or at least partially arrest the symptoms of the disease or condition.
  • amounts effective for this use will depend on the severity and course of the disease or condition, previous therapy, the patient's health status, weight and response to the drugs and the judgment of the treating physician.
  • the amount of a given agent that corresponds to an effective amount varies depending upon factors such as the particular compound, disease or condition and its severity, the identity (e.g., weight) of the subject or host in need of treatment.
  • the effective amount is, nevertheless, determined according to the particular circumstances surrounding the case, including, e.g., the specific agent that is administered, the route of administration, the condition being treated and the subject or host being treated.
  • doses employed for adult human treatment is in the range of about 0.02 to about 5000 mg per day, in a specific embodiment about 1 to about 1500 mg per day.
  • the desired dose is conveniently presented in a single dose or as divided doses administered simultaneously (or over a short period of time) or at appropriate intervals, for example as two, three, four or more sub-doses per day.
  • the pharmaceutical compositions described herein are in a unit dosage form suitable for single administration of precise dosages.
  • the formulation is divided into unit doses containing appropriate quantities of one or more compound.
  • the unit dosage is in the form of a package containing discrete quantities of the formulation.
  • Non-limiting examples are packaged tablets or capsules and powders in vials or ampoules.
  • aqueous suspension compositions are packaged in single-dose non-reclo sable containers.
  • multiple-dose reclosable containers are used, in which case it is typical to include a preservative in the composition.
  • formulations for parenteral injection are, in some embodiments, presented in unit dosage form, which include, but are not limited to ampoules, or in multi-dose containers, with an added preservative.
  • the daily dosages appropriate for the compounds described herein are from about 0.01 to about 20 mg/kg per body weight.
  • an indicated daily dosage in the larger subject including, but not limited to, humans, is in the range from about 0.5 mg to about 1500 mg, conveniently administered in divided doses, including, but not limited to, up to four times a day or in extended release form.
  • suitable unit dosage forms for oral administration comprise from about 1 to about 500 mg active ingredient.
  • the dosages are altered depending on a number of variables, not limited to the activity of the compound used, the disease or condition to be treated, the mode of administration, the requirements of the individual subject, the severity of the disease or condition being treated and the judgment of the practitioner.
  • toxicity and therapeutic efficacy of such therapeutic regimens are determined by standard pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, the determination of the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between the toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD 50 and ED 50 .
  • compounds exhibiting high therapeutic indices are preferred.
  • the data obtained from cell culture assays and animal studies is used in formulating a range of dosage for use in human.
  • the dosage of such compounds lies within a range of circulating concentrations that include the ED 50 with minimal toxicity.
  • the dosage varies within this range depending upon the dosage form employed and the route of administration utilized.
  • Compounds described herein can also be used in combination with other active ingredients, therapeutic agents or treatment modalities. Such combinations are selected based on the condition to be treated, cross-reactivities of ingredients and pharmaco-properties of the combination.
  • a compound as described herein, or pharmaceutically acceptable salt thereof used in combination with another anti-cancer therapy, such as a chemotherapeutic agent, an immunotherapeutic agent, a gene therapeutic agent or a combination thereof.
  • another anti-cancer therapy such as a chemotherapeutic agent, an immunotherapeutic agent, a gene therapeutic agent or a combination thereof.
  • the compounds and compositions provided herein can be combined with other anti-cancer therapeutic agents, surgical procedures, radiation procedures or a combination of any of the foregoing.
  • the treatment methods described herein also contemplate combination therapy.
  • a compound of the disclosure with one or more other active ingredients in a unitary dosage form for simultaneous or sequential administration to a patient.
  • the combination therapy may be administered as a simultaneous or sequential regimen.
  • the combination may be administered in two or more administrations.
  • kits for treating cancer comprising a compound or composition described herein are provided.
  • the kit comprises a unit dose of a compound or composition described herein and instructions for administering the same.
  • the kit further comprises a second drug suitable for anti-cancer therapy, or instructions for co-administering an additional anti-cancer therapy (such as radiation or gene therapy).
  • kits for use to achieve anti-cancer effects comprise less than about 500 mg/day, or less than about 400 mg/day, or less than about 300 mg/day, or less than about 200 mg/day of a compound or composition described herein and a second drug suitable for anti-cancer therapy.
  • kits for use to achieve anti-cancer effects comprise a greater than about 500 mg/day of a compound or composition as described herein and a second drug suitable for anti-cancer therapy.
  • a particular enantiomer of a compound this may be accomplished from a corresponding mixture of enantiomers using any suitable conventional procedure for separating or resolving enantiomers.
  • diastereomeric derivatives may be produced by reaction of a mixture of enantiomers, e.g. a racemate, and an appropriate chiral compound. The diastereomers may then be separated by any convenient means, for example by crystallization and the desired enantiomer recovered.
  • a racemate may be separated using chiral High-Performance Liquid Chromatography.
  • a particular enantiomer may be obtained by using an appropriate chiral intermediate in one of the processes described.
  • Chromatography, recrystallization and other conventional separation procedures may also be used with intermediates or final products where it is desired to obtain a particular isomer of a compound or to otherwise purify a product of a reaction.
  • Step 1 Synthesis of ethyl-1-benzyl-5-oxoazepane-4-carboxylate.
  • l-benylpiperidin-4-one 20.0 g, 105.7 mmol
  • MTBE 400 mL
  • BF ⁇ EbO (19.5 mL, 137.4 mmol, 1.3 eq) dropwise for 10 min
  • ethyl diazoacetate 80% in CH2CI2, 22.6 mL, 158.5 mmol, 1.5 eq
  • reaction mixture was cooled to 0 °C, quenched with 30% aqueous K2CO3 solution (500 mL).
  • the biphasic solution was separated, and the aqueous layer was extracted with EtOAc (2 x 200 mL).
  • EtOAc 2 x 200 mL
  • the combined organic layers were dried over Na2S04, filtered, concentrated under reduced pressure, and purified by silica gel chromatography to afford the title compound.
  • Step 2 Synthesis of 7-benzyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine- 2,4-diol.
  • ethyl-1-benzyl-5-oxoazepane-4-carboxylate 4.0 g, 14.5 mmol, 1.0 eq
  • EtOH 40 mL
  • urea 1.30 g, 21.7 mmol, 1.5 eq
  • Step 3 Synthesis of 7-benzyl-2,4-dichloro-6,7,8,9-tetrahydro-5H- pyrimido[4,5-d]azepine.
  • the reaction mixture was cooled to RT, poured in ice cold water and basified to pH 8-10 using aqueous saturated NaHCCL and extracted with CH2CI2 (3 x 100 mL).
  • Step 4 Synthesis of tert-butyl-4-(7-benzyl-2-chloro-6,7,8,9-tetrahydro-5H- pyrimido[4,5-d]azepin-4-yl)piperazine-1-carboxylate.A solution of 7 -benzyl-2, 4-dichloro-
  • Step 5 Synthesis of tert-butyl (S)-4-(7-benzyl-2-((l-methylpyrrolidin-2- yl)methoxy)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl)piperazine-1- carboxylate.
  • NaH 50% in mineral oil, 0.09 g, 2.28 mmol, 3.0 eq
  • dry THF 5 mL
  • N-methyl-L-prolinol 0.1 mL, 0.92 mmol, 1.2 eq
  • Step 6 Synthesis of tert-butyl (S)-4-(2-((l-methylpyrrolidin-2-yl)methoxy)-
  • Step 7 Synthesis of tert-butyl (S)-4-(7-(8-methylnaphthalen-1-yl)-2-((l- methylpyrrolidin-2-yl)methoxy)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4- yl)piperazine-1-carboxylate (Isomer A and Isomer B).
  • the reaction mixture was degassed with argon for 10 min and followed by addition of RuPhos (0.09 g, 0.20 mmol, 0.3 eq), RuPhos-Pd-G3 (0.11 g, 0.13 mmol, 0.2 eq) under argon.
  • the reaction mixture was stirred at 100 °C for 72 h.
  • the reaction mixture was cooled to RT, diluted with EtOAc (10 mL), washed with water (10 mL).
  • the aqueous layer was extracted using EtOAc (2 x 10 mL).
  • the combined organic layers were dried over Na 2 S0 4 and concentrated in vacuo.
  • the resulting crude material was purified by silica gel chromatography to afford the title compound as Isomer A and Isomer B.
  • Step 8 Synthesis of (S)-7-(8-methylnaphthalen-1-yl)-2-((l-methylpyrrolidin- 2-yl)methoxy)-4-(piperazin-1-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine (Isomer A and Isomer B).
  • Step 9 Synthesis of (S)-1-(4-(7-(8-methylnaphthalen-1-yl)-2-((l- methylpyrrolidin-2-yl)methoxy)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4- yl)piperazin-1-yl)prop-2-en-1-one (Isomer A and Isomer B).
  • reaction mixture was quenched with aqueous saturated NaHCCL (5 ruL), extracted with CH2CI2 (2 x 15 ruL). The combined organic layers were dried over Na 2 S0 4 and concentrated to obtain crude material. The obtained crude material was purified by preparative HPLC.
  • Example S-2 Synthesis of2-((S)-l-Acryloyl-4-(7-(8-methylnaphthalen-l-yl)-2-(((S)-l- methylpyrrolidin-2-yl )methoxy )-6, 7, 8, 9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl )piperazin- 2-yl)acetonitrile (Compound 72, Isomer A and Isomer B)
  • Step 1 Synthesis of tert-butyl-(S)-4-(7-benzyl-2-chloro-6,7,8,9-tetrahydro- 5H-pyrimido[4,5-d]azepin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate.
  • the reaction mixture was diluted with cold water (20 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layers were dried over Na 2 S0 4, filtered, and concentrated in vacuo. The crude material was purified by silica gel chromatography to afford the title compound.
  • Step 2 Synthesis of tert-butyl-(S)-4-(7-benzyl-2-(((S)-1-methylpyrrolidin-2- yl)methoxy)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl)-2- (cyanomethyl)piperazine-1-carboxylate.
  • N-methyl-L-prolinol (0.42 g, 3.62 mmol, 1.5 eq) in dry THE (20 mL) at 0 °C was added sodium tert-butoxide (0.46 g, 4.82 mmol, 2.0 eq) and stirred for 30 min.
  • Step 3 Synthesis of tert-butyl (S)-2-(cyanomethyl)-4-(2-(((S)-1- methylpyrrolidin-2-yl)methoxy)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4- yl)piperazine-1-carboxylate.
  • Step 4 Synthesis of tert-butyl (S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen- l-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-6,7,8,9-tetrahydro-5H-pyrimido[4,5- d]azepin-4-yl)piperazine-1-carboxylate.
  • Step 5 Synthesis of 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1- methylpyrrolidin-2-yl)methoxy)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4- yl)piperazin-2-yl)acetonitrile.
  • Step 6 Synthesis of 2-((S)-1-Acryloyl-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)- l-methylpyrrolidin-2-yl)methoxy)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4- yl)piperazin-2-yl)acetonitrile.
  • Example S-3 Synthesis of2-((S)-l-acryloyl-4-(7-(5-methyl-lH-indazol-4-yl)-2-(((S)-l-methyl pyrrolidin-2-yl )methoxy)-6, 7, 8, 9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl )piperazin-2 -yl ) acetonitrile ( Compound 52 )
  • Step 1 Synthesis of tert-butyl (S)-2-(cyanomethyl)-4-(7-(5-methyl-lH- indazol-4-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-6,7,8,9-tetrahydro-5H- pyrimido[4,5-d]azepin-4-yl)piperazine-1-carboxylate.
  • Step 2 Synthesis of 2-((S)-4-(7-(5-methyl-lH-indazol-4-yl)-2-(((S)-1- methylpyrrolidin-2-yl)methoxy)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4- yl)piperazin-2-yl)acetonitrile.
  • Step 3 Synthesis of 2-((S)-1-acryloyl-4-(7-(5-methyl-lH-indazol-4-yl)-2-(((S)- l-methylpyrrolidin-2-yl)methoxy)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4- yl)piperazin-2-yl)acetonitrile.
  • reaction mixture was quenched with aqueous saturated NaHC0 3 (10 mL) and extracted with DCM (2 x 15 mL). The combined organic layers were dried over Na 2 S0 4 , filtered, and concentrated under reduced pressure to obtain crude material. The crude material was purified by preparative HPLC and SEC to afford the title compound.
  • Example S-4 Synthesis of2-((S)-l-((E)-but-2-enoyl)-4-(7-(5-methyl-lH-indazol-4-yl)-2-(((S)- l-methylpyrroUdin-2-yl)methoxy)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4- yl)piperazin-2-yl)acetonitrile (Compound 80)
  • Method I A biochemical assay to assess activity of test compounds in inhibiting SOS 1 -mediated exchange of GDP for GTP on the KRAS G12C protein was performed at Reaction Biology Corporation (Malvern, PA, USA). In this assay, exchange of BODIPY- GDP to GTP results in the decrease in BODIPY-GDP fluorescence. Briefly, recombinant KRAS G12C protein (aa 2-169, prepared by Reaction Biology) was labelled with 5x excess of BODIPY-GDP. Excess BODIPY-GDP was separated from loaded protein using a gravity desalting column. Compounds were incubated with 0.15 mM KRAS G12C/BODIPY-GDP for 30 minutes.
  • Method II Method II.
  • an assay using Mant-GDP instead of BODIPY-GDP is performed at Reaction Biology Corporation (Malvern, PA, USA).
  • Reaction Biology Corporation Reaction Biology Corporation
  • exchange of Mant-GDP to GTP results in the decrease in Mant-GDP fluorescence.
  • recombinant KRAS G12C protein (aa 2-169, prepared by Reaction Biology) is labelled with lOx excess of Mant-GDP.
  • Excess Mant-GDP is separated from loaded protein using a desalting column (AKTA system). Compounds are incubated with 0.5 mM KRAS G12C/Mant GDP for 30 min.
  • GTP (25 mM) is added to the reaction mixture and the mixture further incubated for 5 min.
  • Method III Inhibition of SOS 1 -mediated exchange of GDP for GTP on the KRAS G12C protein was measured in a biochemical assay that monitors association of KRAS G12C protein with the Ras-binding domain of Raf (Raf-RBD), where the association is coupled to exchange of GDP to GTP on the KRAS G12C protein.
  • the assay was performed at WuXi AppTec (Shanghai, China). Compounds were serially diluted in 3-fold dilutions to 11 concentrations and spotted into the wells of an assay plate in a total volume of 150 nL DMSO per well.
  • a 2X enzyme mix was prepared by diluting GDP-bound, His-tagged KRAS G12C to 25 nM in assay buffer. 10 ⁇ L/well of 2X enzyme mix was added to all wells, and the plate was sealed and incubated overnight (18 hr) at 23 °C. 4X SOS 1/GDP and 4X SOS1/GTP were prepared in assay buffer. 5 ⁇ L/well of 4X SOS 1/GDP mix was added to negative control wells, 5 ⁇ L/well of 4X SOS1/GTP mix was added to the remaining wells, and the plate was further incubated at 23 °C for 1 hr.
  • MIA PaCa-2 (ATCC CRL-1420), a pancreatic carcinoma cell line having the KRAS G12C mutation, is seeded in medium (DMEM with 10% FBS and 2.5% horse serum) at a cell count of 1700 cells per 100 ⁇ L per well in a 96 well edge plate (167425; ThermoFisher). Cells are incubated at 37 °C for 24 hr in 5% CO2 environment (culture conditions) in a Nuaire incubator (humidified). Serially diluted test compounds (100 ⁇ L) within the desired testing concentration ranges are added to the culture plate and the cells are further incubated in culture conditions for 72 h.
  • medium DMEM with 10% FBS and 2.5% horse serum
  • the experiment is terminated at the designated incubation time by replacing the medium with 100 ⁇ L of 1 mM of resazurin (R7017; Sigma) prepared in culture medium, and the plates are further incubated in culture conditions for 4-6 h. Fluorescence is recorded using a multimodal plate reader (Biotek Synergy Neo) at an excitation wavelength of 535 nm and emission wavelength of 590 nm to obtain relative fluorescence units. Data are analyzed as follows: the background fluorescence (blank containing only medium) value is subtracted from each reading and normalized with the vehicle control (DMSO treated cells) to obtain percent survival/proliferation. Percent survival is subtracted from 100 to get the percent inhibition of proliferation which is used to calculate IC50 values.
  • Potency of compounds in A549 (ATCC CCL-185), a non-small cell lung cancer cell line harboring the KRAS G12S mutation, is determined in an analogous manner, except that the cells are seeded in medium (DMEM with 10% FBS) at a cell count of 2000 cells per 100 ⁇ L per well.
  • medium DMEM with 10% FBS
  • Potency of compounds is determined in cell proliferation assays in a panel of cancer cell lines.
  • Cells are seeded in 384-well plates (Coming, Cat. #3765) at specified densities in 40 ⁇ L of culture medium and incubated overnight at 37 °C in a 5% CO2 incubator (culture conditions). Medium and seeding density for each cell line is shown in Table 3.
  • serially diluted test compounds are added in a volume of 20 nL DMSO to wells in the culture plate to achieve the final desired concentrations of test compounds, and the cells are further incubated in culture conditions for 72 hr.
  • the assay is terminated by addition of 25 ⁇ L of Cell Titer-Glo reagent (Promega, Madison, WI) to each well. Contents are mixed, the plate is incubated for 10 min at room temperature and luminescence is measured. The IC50 value of each test compound is calculated with XLFit curve fitting software.
  • NCI-H358 cells (ATCC ® CRL-5807 TM ) are plated in a 384-well Black/Clear Round Bottom Ultra-Low Attachment Microplate (Corning) in medium (RPMI-1640 + 10% FBS) at a density of 1000 cells in 50 ⁇ L per well, then incubated overnight at 37°C and 5% CO2. Cells are treated with test compounds at 9 concentrations within a specified concentration range (e.g., 0.5 nM - 10 pM) for generation of dose response curves.
  • a specified concentration range e.g., 0.5 nM - 10 pM
  • Test compounds are prepared by 1:3 serial dilution in DMSO from a specified starting concentration (e.g., 20 pM, 2 pM or 0.2 pM) and then added to wells of the assay plate in a total volume of 150 nL DMSO. The cells are further incubated at 37°C and 5% CO2 for 7 days. Cell viability is assessed by adding 40 ⁇ L of Cell Titer-Glo® 3D reagent (Cat. No.: G9683, Promega) to each well and reading luminescence after mixing and incubation of the samples. The IC50 value of each test compound is calculated with XLFit curve fitting software.
  • MIA PaCa-2, NCTH358 or other cancer cells are seeded in 10-cm dishes and incubated overnight in a 5% CO2 incubator at 37 °C. Cells are then treated with test compound or vehicle which is added to the culture dish for a specified duration. Following treatment, they are washed twice with PBS and lysed in lysis buffer (25 mM Tris-HCl, pH 7.2, 150 mM NaCl, 5 mM MgCh, 5% glycerol, 1% NP40) supplemented with phosphatase and protease inhibitors. Proteins from the lysates are separated by standard SDS-PAGE methods.
  • proteins are blotted onto nitrocellulose membranes which are then blocked and incubated with primary antibodies specific for target proteins such as RAS, KRAS, phospho-ERK, ERK, phospho-AKT, AKT, phospho-S6 or others. After the primary antibody incubation, membranes are incubated with HRP-linked secondary antibody, and proteins are detected by a chemiluminescence detection method.
  • target proteins such as RAS, KRAS, phospho-ERK, ERK, phospho-AKT, AKT, phospho-S6 or others.
  • Method I Phosphorylation of ERK is assessed by an AlphaScreen® assay (e.g., AlphaScreen® SureFire® pERKl/2 (Thr202/Tyr204) assay, Perkin Elmer).
  • AlphaScreen® assay e.g., AlphaScreen® SureFire® pERKl/2 (Thr202/Tyr204) assay, Perkin Elmer.
  • MIA PaCa-2, NCI-H358 or other cancer cells are seeded in 96-well plates and incubated overnight in a 5% CO2 incubator at 37 °C. The culture medium is then removed and replaced with serum-free medium containing serially diluted compound or DMSO. After further incubation at 37 °C, medium is removed and cells are lysed by addition of IX Lysis Buffer and agitation on a plate shaker.
  • a portion of the lysate is transferred to an assay plate.
  • Reaction Mix containing Reaction buffer, Activation buffer and AlphaScreen beads is added to the lysate, the plate is briefly agitated on a plate shaker and then incubated at room temperature for a desired duration.
  • the plate is read on an AlphaS creen-compatible fluorescence plate reader (520-620 nm emission) and dose response curves are analyzed using 4-parameter non-linear regression.
  • Method II Phosphorylation of ERK is assessed by a homogeneous TR-FRET assay (Advanced phospho-ERK (Thr202/Tyr204) cellular kit; Cat. #64AERPEH, Cisbio).
  • TR-FRET assay Advanced phospho-ERK (Thr202/Tyr204) cellular kit; Cat. #64AERPEH, Cisbio.
  • NCI-H358 cells are seeded in a 384-well culture plate at a density of 6000 cells in 40 ⁇ L medium/well and grown overnight at 37 °C and 5% CO2. Each test compound is dosed in duplicate in a 10-dose 3-fold titration starting at 10 mM or 2 mM. The culture plate is then incubated for 4 hr in the incubator.
  • the medium is removed, 35 ⁇ L of lysis buffer is added to each well, and the plate is agitated on a plate shaker for 40 mins at 4 °C.
  • An antibody cocktail of phospho-ERKl/2 Eu Cryptate antibody and Phospho-ERKl/2 d2 antibody is prepared by separately diluting the antibodies 20-fold with detection buffer and then mixing them together. 3.4 ⁇ L of antibody cocktail is dispensed to each well of an empty 384-well white ProxiPlus assay plate (Perkin Elmer), and the plate briefly centrifuged. 13.6 ⁇ L of cell lysate is then added to the antibody-containing wells, and the plate is briefly centrifuged and then incubated 2 hr at room temperature.
  • the plate is read on a fluorescence plate reader (Envision2104, Perkin Elmer), with an excitation wavelength of 337 nm and emission wavelengths of 615 nm and 665 nm.
  • the IC50 value of each test compound is calculated with XLFit curve fitting software.
  • Example B10 Evaluation of test compound in NCI-E1358 mouse xenograft model
  • NCTH358 cells are injected subcutaneously (5xl0 6 cells in 0.1 mL of PBS) into the right flanks of 6-8-week-old female B ALB/c nude mice and allowed to grow until the average tumor size reaches 150-200 mm 3 .
  • the mice are then stratified into treatment groups of 4-8 animals and treatment initiated at Day 0.
  • Test compound or vehicle 1% Tween 80, 2% HPMC, and 97% water is administered orally, once daily, for 21 days.
  • TGI% (1-Ti/Vi) x 100
  • MIA PaCa-2 mice xenograft model To examine the in vivo antitumor activity of test compound, tumor growth experiments are performed in a MIA PaCa-2 mouse xenograft model. MIA PaCa-2 cells are injected subcutaneously (lOxlO 6 cells in 0.2 mL of PBS with Matrigel (1:1)) into the right flanks of 6-8-week-old female BALB/c nude mice and allowed to grow until the average tumor size reaches 150-200 mm 3 . The mice are then stratified into treatment groups of 8 animals and treatment initiated at Day 0. Test compound or vehicle (1% Tween 80, 2% HPMC, and 97% water) is administered orally, once daily, for 14 days with an observational phase to monitor tumor growth post-treatment.
  • Test compound or vehicle 1% Tween 80, 2% HPMC, and 97% water

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des inhibiteurs d'une ou de plusieurs isoformes de RAS, tels que des inhibiteurs de KRAS, HRAS et/ou NRAS, ou des mutants de ceux-ci, tels que des mutants G12D, G12V, G13D ou G12C de ceux-ci. L'invention concerne également des méthodes thérapeutiques de traitement d'états et de maladies à l'aide de ces inhibiteurs.
PCT/US2021/036025 2020-06-05 2021-06-04 Composés hétérocycliques et leurs procédés d'utilisation WO2021248083A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063035655P 2020-06-05 2020-06-05
US63/035,655 2020-06-05
US202163173328P 2021-04-09 2021-04-09
US63/173,328 2021-04-09

Publications (1)

Publication Number Publication Date
WO2021248083A1 true WO2021248083A1 (fr) 2021-12-09

Family

ID=78830602

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/036025 WO2021248083A1 (fr) 2020-06-05 2021-06-04 Composés hétérocycliques et leurs procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2021248083A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11453683B1 (en) 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
WO2022235870A1 (fr) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Inhibiteurs de ras pour le traitement du cancer
WO2022235864A1 (fr) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Inhibiteurs de ras
WO2022266206A1 (fr) 2021-06-16 2022-12-22 Erasca, Inc. Conjugués d'inhibiteurs de kras
US11548888B2 (en) 2019-01-10 2023-01-10 Mirati Therapeutics, Inc. KRas G12C inhibitors
US11702418B2 (en) 2019-12-20 2023-07-18 Mirati Therapeutics, Inc. SOS1 inhibitors
WO2023172940A1 (fr) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Méthodes de traitement du cancer du poumon réfractaire immunitaire
WO2023240263A1 (fr) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Inhibiteurs de ras macrocycliques
US11845761B2 (en) 2020-12-18 2023-12-19 Erasca, Inc. Tricyclic pyridones and pyrimidones
US11890285B2 (en) 2019-09-24 2024-02-06 Mirati Therapeutics, Inc. Combination therapies
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020039028A1 (fr) * 2018-08-22 2020-02-27 Asceneuron S. A. Inhibiteurs de tétrahydro-benzoazépine glycosidase
WO2020047192A1 (fr) * 2018-08-31 2020-03-05 Mirati Therapeutics, Inc. Inhibiteurs de kras g12c

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020039028A1 (fr) * 2018-08-22 2020-02-27 Asceneuron S. A. Inhibiteurs de tétrahydro-benzoazépine glycosidase
WO2020047192A1 (fr) * 2018-08-31 2020-03-05 Mirati Therapeutics, Inc. Inhibiteurs de kras g12c

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEM SUBSTANCE 5 November 2019 (2019-11-05), ANONYMOUS : "tert-Butyl 3-(2-chloroquinolin-4-yl)azetidine-1- carboxylate", XP055880720, retrieved from PUBCHEM Database accession no. 376079997 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
US11548888B2 (en) 2019-01-10 2023-01-10 Mirati Therapeutics, Inc. KRas G12C inhibitors
US11453683B1 (en) 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
US11964989B2 (en) 2019-08-29 2024-04-23 Mirati Therapeutics, Inc. KRas G12D inhibitors
US11890285B2 (en) 2019-09-24 2024-02-06 Mirati Therapeutics, Inc. Combination therapies
US11702418B2 (en) 2019-12-20 2023-07-18 Mirati Therapeutics, Inc. SOS1 inhibitors
US11845761B2 (en) 2020-12-18 2023-12-19 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022235870A1 (fr) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Inhibiteurs de ras pour le traitement du cancer
WO2022235864A1 (fr) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Inhibiteurs de ras
WO2022266206A1 (fr) 2021-06-16 2022-12-22 Erasca, Inc. Conjugués d'inhibiteurs de kras
WO2023172940A1 (fr) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Méthodes de traitement du cancer du poumon réfractaire immunitaire
WO2023240263A1 (fr) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Inhibiteurs de ras macrocycliques

Similar Documents

Publication Publication Date Title
WO2021248083A1 (fr) Composés hétérocycliques et leurs procédés d'utilisation
US20230023009A1 (en) Heterocyclic compounds and methods of use thereof
WO2021248079A1 (fr) Composés hétérocycliques et leurs procédés d'utilisation
WO2021248082A1 (fr) Composés hétérocycliques et leurs procédés d'utilisation
WO2021248095A1 (fr) Composés hétérocycliques et leurs procédés d'utilisation
JP6678655B2 (ja) Ｒａｆキナーゼ阻害剤としての化合物および組成物
CN111315747B (zh) 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
US11292782B2 (en) Diarylhydantoin compounds and methods of use thereof
US11034669B2 (en) Pyrrole and pyrazole compounds and methods of use thereof
US10336734B2 (en) Inhibitors of ACK1/TNK2 tyrosine kinase
EP2861578A1 (fr) Composés et compositions destinés à la modulation de l'activité de l'egfr
US11932647B2 (en) Cyclic iminopyrimidine derivatives as kinase inhibitors
EP4043450A1 (fr) Dérivés 2h-benzopyrane utilisables en tant qu'inhibiteurs de crac
EA026655B1 (ru) 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
US9464093B2 (en) Substituted imidazo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines and oxazolo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines for treating brain cancer
CN108463222B (zh) 用于治疗疾病的杂环化合物
TW201516048A (zh) Ｂｃｒ－ａｂｌ激酶抑制劑及其應用
EP4382530A1 (fr) Inhibiteur de shp2, composition pharmaceutique le comprenant et son application
US20230095530A1 (en) Compound used as ret kinase inhibitor and application thereof
AU2020281411A1 (en) Tetracyclic compounds as Cdc7 inhibitors
JP2022532520A (ja) 癌を処置するための化合物
US20080139608A1 (en) 2,6,8, Trisubstituted 1-deazapurines and their different uses
EP3049400B1 (fr) Nouveaux inhibiteurs pi3k/akt/mtor et leurs utilisations pharmaceutiques
EP2970138B1 (fr) Dérivés de pyrazole et leurs utilisations
EP3886848A1 (fr) Composés pharmaceutiques et méthodes thérapeutiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21818860

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A XXXX DATED 29/03/2023)

122 Ep: pct application non-entry in european phase

Ref document number: 21818860

Country of ref document: EP

Kind code of ref document: A1